Wanbangde Pharmaceutical Holding Group Co Ltd (002082) - Net Assets

Latest as of March 2026: CN¥2.70 Billion CNY ≈ $394.62 Million USD

Based on the latest financial reports, Wanbangde Pharmaceutical Holding Group Co Ltd (002082) has net assets worth CN¥2.70 Billion CNY (≈ $394.62 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥4.55 Billion ≈ $666.34 Million USD) and total liabilities (CN¥1.86 Billion ≈ $271.72 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Wanbangde Pharmaceutical Holding Group C asset portfolio for the complete picture of this company's asset base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥2.70 Billion
% of Total Assets	59.22%
Annual Growth Rate	16.05%
5-Year Change	-4.99%
10-Year Change	86.71%
Growth Volatility	30.7

Wanbangde Pharmaceutical Holding Group Co Ltd - Net Assets Trend (2003–2025)

This chart illustrates how Wanbangde Pharmaceutical Holding Group Co Ltd's net assets have evolved over time, based on quarterly financial data. Check 002082 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Annual Net Assets for Wanbangde Pharmaceutical Holding Group Co Ltd (2003–2025)

The table below shows the annual net assets of Wanbangde Pharmaceutical Holding Group Co Ltd from 2003 to 2025. For live valuation and market cap data, see 002082 market cap.

Year	Net Assets	Change
2025-12-31	CN¥2.61 Billion ≈ $381.57 Million	-5.40%
2024-12-31	CN¥2.76 Billion ≈ $403.35 Million	-0.09%
2023-12-31	CN¥2.76 Billion ≈ $403.72 Million	-2.13%
2022-12-31	CN¥2.82 Billion ≈ $412.52 Million	+2.71%
2021-12-31	CN¥2.74 Billion ≈ $401.63 Million	-3.97%
2020-12-31	CN¥2.86 Billion ≈ $418.23 Million	+49.50%
2019-12-31	CN¥1.91 Billion ≈ $279.76 Million	+10.92%
2018-12-31	CN¥1.72 Billion ≈ $252.22 Million	+7.49%
2017-12-31	CN¥1.60 Billion ≈ $234.64 Million	+14.81%
2016-12-31	CN¥1.40 Billion ≈ $204.36 Million	+3.68%
2015-12-31	CN¥1.35 Billion ≈ $197.11 Million	+3.91%
2014-12-31	CN¥1.30 Billion ≈ $189.69 Million	+9.13%
2013-12-31	CN¥1.19 Billion ≈ $173.83 Million	+8.24%
2012-12-31	CN¥1.10 Billion ≈ $160.59 Million	+4.11%
2011-12-31	CN¥1.05 Billion ≈ $154.24 Million	+12.60%
2010-12-31	CN¥936.13 Million ≈ $136.98 Million	+15.34%
2009-12-31	CN¥811.59 Million ≈ $118.76 Million	+13.94%
2008-12-31	CN¥712.31 Million ≈ $104.23 Million	+71.59%
2007-12-31	CN¥415.12 Million ≈ $60.74 Million	+16.04%
2006-12-31	CN¥357.72 Million ≈ $52.35 Million	+133.99%
2005-12-31	CN¥152.88 Million ≈ $22.37 Million	+12.27%
2004-12-31	CN¥136.17 Million ≈ $19.93 Million	+38.21%
2003-12-31	CN¥98.53 Million ≈ $14.42 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Wanbangde Pharmaceutical Holding Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 3553.7% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	CN¥1.49 Billion	59.07%
Other Components	CN¥1.03 Billion	40.93%
Total Equity	CN¥2.52 Billion	100.00%

Wanbangde Pharmaceutical Holding Group Co Ltd Competitors by Market Cap

The table below lists competitors of Wanbangde Pharmaceutical Holding Group Co Ltd ranked by their market capitalization.

Company	Market Cap
Center Laboratories TWO:4123	$895.11 Million
Shanghai Aladdin Biochemical Technology Co. Ltd. A SHG:688179	$895.24 Million
Country Garden Holdings Company Limited F:DZJ	$895.26 Million
MONGOLIAN MINING CRP.REGS F:29X2	$895.28 Million
Zhejiang Baoxiniao Garment Co Ltd SHE:002154	$894.76 Million
Gansu Yasheng Industrial Group Co Ltd SHG:600108	$894.57 Million
GrocerIQ, Inc NYSE:WPFHD	$894.41 Million
Cullinan Oncology LLC NASDAQ:CGEM	$894.21 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Wanbangde Pharmaceutical Holding Group Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 2,666,804,346 to 2,515,929,479, a change of -150,874,867 (-5.7%).
Net loss of 198,777,200 reduced equity.
Dividend payments of 47,698,498 reduced retained earnings.
Other comprehensive income decreased equity by 156,814,283.
Other factors increased equity by 252,415,115.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	CN¥-198.78 Million	-7.9%
Dividends Paid	CN¥47.70 Million	-1.9%
Other Comprehensive Income	CN¥-156.81 Million	-6.23%
Other Changes	CN¥252.42 Million	+10.03%
Total Change	CN¥-	-5.66%

Book Value vs Market Value Analysis

This analysis compares Wanbangde Pharmaceutical Holding Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.47x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 62.75x to 2.47x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2003-12-31	CN¥0.16	CN¥10.00	x
2004-12-31	CN¥0.20	CN¥10.00	x
2005-12-31	CN¥0.34	CN¥10.00	x
2006-12-31	CN¥0.84	CN¥10.00	x
2007-12-31	CN¥1.93	CN¥10.00	x
2008-12-31	CN¥3.05	CN¥10.00	x
2009-12-31	CN¥3.38	CN¥10.00	x
2010-12-31	CN¥3.89	CN¥10.00	x
2011-12-31	CN¥4.42	CN¥10.00	x
2012-12-31	CN¥4.52	CN¥10.00	x
2013-12-31	CN¥4.96	CN¥10.00	x
2014-12-31	CN¥5.38	CN¥10.00	x
2015-12-31	CN¥5.52	CN¥10.00	x
2016-12-31	CN¥5.75	CN¥10.00	x
2017-12-31	CN¥5.93	CN¥10.00	x
2018-12-31	CN¥4.14	CN¥10.00	x
2019-12-31	CN¥3.28	CN¥10.00	x
2020-12-31	CN¥4.32	CN¥10.00	x
2021-12-31	CN¥4.21	CN¥10.00	x
2022-12-31	CN¥4.32	CN¥10.00	x
2023-12-31	CN¥4.32	CN¥10.00	x
2024-12-31	CN¥4.33	CN¥10.00	x
2025-12-31	CN¥4.05	CN¥10.00	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Wanbangde Pharmaceutical Holding Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -7.90%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -17.36%
• Asset Turnover: 0.26x
• Equity Multiplier: 1.75x
Recent ROE (-7.90%) is below the historical average (9.83%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2003	20.54%	4.86%	1.59x	2.65x	CN¥10.38 Million
2004	20.41%	4.80%	1.29x	3.31x	CN¥13.10 Million
2005	14.92%	1.82%	1.77x	4.62x	CN¥7.05 Million
2006	9.34%	0.88%	4.39x	2.41x	CN¥-2.35 Million
2007	15.52%	1.30%	5.27x	2.26x	CN¥22.62 Million
2008	10.49%	1.27%	5.71x	1.45x	CN¥3.48 Million
2009	15.08%	1.91%	5.67x	1.39x	CN¥40.76 Million
2010	16.45%	1.89%	6.12x	1.42x	CN¥59.59 Million
2011	15.15%	1.46%	7.52x	1.38x	CN¥53.96 Million
2012	7.96%	0.79%	7.00x	1.44x	CN¥-22.16 Million
2013	9.47%	0.95%	7.61x	1.31x	CN¥-6.26 Million
2014	8.36%	0.94%	7.38x	1.21x	CN¥-21.04 Million
2015	4.71%	0.54%	7.16x	1.21x	CN¥-70.66 Million
2016	5.04%	0.76%	5.54x	1.20x	CN¥-68.54 Million
2017	6.91%	0.67%	6.97x	1.48x	CN¥-43.94 Million
2018	10.87%	22.03%	0.26x	1.91x	CN¥12.91 Million
2019	17.98%	1.76%	4.39x	2.32x	CN¥130.69 Million
2020	10.87%	2.08%	2.42x	2.16x	CN¥22.77 Million
2021	6.41%	8.62%	0.44x	1.68x	CN¥-93.33 Million
2022	3.47%	5.22%	0.42x	1.57x	CN¥-175.55 Million
2023	1.85%	3.19%	0.36x	1.62x	CN¥-216.56 Million
2024	2.08%	3.84%	0.33x	1.62x	CN¥-211.24 Million
2025	-7.90%	-17.36%	0.26x	1.75x	CN¥-450.37 Million

Industry Comparison

This section compares Wanbangde Pharmaceutical Holding Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $2,536,896,341
Average return on equity (ROE) among peers: 9.73%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Wanbangde Pharmaceutical Holding Group Co Ltd (002082)	CN¥2.70 Billion	20.54%	0.69x	$895.09 Million
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$692.59 Million	2.04%	3.57x	$642.98 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$1.15 Billion	3.57%	0.95x	$376.71 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$377.25 Million	11.95%	0.42x	$5.22 Billion
Livzon Pharmaceutical Group Inc (000513)	$973.90 Million	0.17%	0.60x	$2.67 Billion
Wedge Industrial Co Ltd (000534)	$760.85 Million	18.95%	0.28x	$1.86 Billion
Yunnan Baiyao Group Co Ltd (000538)	$7.04 Billion	22.50%	0.52x	$13.65 Billion
Hainan Haiyao Co Ltd (000566)	$292.94 Million	7.42%	0.73x	$1.08 Billion
Tus Pharmaceutical Group Co Ltd (000590)	$280.91 Million	1.46%	1.58x	$299.61 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$4.71 Billion	7.43%	1.93x	$964.78 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$9.09 Billion	21.79%	0.11x	$3.21 Billion

About Wanbangde Pharmaceutical Holding Group Co Ltd

SHE:002082 China Drug Manufacturers - Specialty & Generic

Market Cap

$895.09 Million

CN¥6.12 Billion CNY

Market Cap Rank

#9278 Global

#2294 in China

Share Price

CN¥10.00

Change (1 day)

+1.94%

52-Week Range

CN¥7.19 - CN¥36.24

All Time High

CN¥36.24